D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
Vasculitis working group: Selected unanswered questions related to giant cell arteritis and anti-neutrophil cytoplasmic antibody-associated vasculitis
TL;DR: It is shown that more research is needed to provide a firmer body of evidence to support clinical decision-making for patients with vasculitis, and several immunosuppressive agents can be used for maintenance therapy after induction of remission in patients with ANCA-associated vasculopathy.
Proceedings ArticleDOI
FRI0498 Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab
TL;DR: Only VLDA, but not MDA, could match the stringency of DAPSA remission, a finding that was confirmed through analysis of the ACCLAIM cohort.
Journal ArticleDOI
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
Robert Landewé,Josef S. Smolen,Michael E. Weinblatt,Paul Emery,Paul Emery,Maxime Dougados,Roy Fleischmann,Daniel Aletaha,Arthur Kavanaugh,Désirée van der Heijde +9 more
TL;DR: A shortlist of points-to-consider when designing, performing and reporting investigator-initiated trials is proposed, covering three themes: (1) design choice (superiority vs non-inferiority designs); (2) statistical power and (3) convenience reporting.
Journal ArticleDOI
Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
M. Gärtner,I K Sigmund,Farideh Alasti,G. Supp,Helga Radner,Klaus P Machold,Josef S Smolen,Daniel Aletaha +7 more
TL;DR: Investigation of the duration of clinical inactivity as a marker for non-progression on the joint level found full clinical remission is an excellent marker of structural stability in patients with RA, and the maintenance of this state reduces the risk of progression even further.
Journal ArticleDOI
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Daniel Aletaha,Andreas Kerschbaumer,Kastriot Kastrati,Christian Dejaco,Maxime Dougados,Iain B. McInnes,Naveed Sattar,Tanja Stamm,Y. Takeuchi,Michael Trauner,Désirée van der Heijde,Marieke Voshaar,Kevin L. Winthrop,Angelo Ravelli,Neil Betteridge,Gerd R Burmester,Johannes W. J. Bijlsma,Vivian P. Bykerk,Roberto Caporali,Ernest Choy,Catalin Codreanu,Bernard Combe,Mary K. Crow,Maarten de Wit,Paul Emery,Roy Fleischmann,Cem Gabay,Merete Lund Hetland,Kimme L. Hyrich,Annamaria Iagnocco,John T. Isaacs,Joel M. Kremer,Xavier Mariette,Petra Merkel,Eduardo Mysler,Peter Nash,Michael T. Nurmohamed,Karel Pavelka,Gyula Poór,Andrea Rubbert-Roth,Hendrik Schulze-Koops,Anja Strangfeld,Yoshiya Tanaka,Josef S Smolen +43 more
TL;DR: An update of a previous consensus document, based on most recent evidence and expert opinion, provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals, patients, administrators and payers.